Skip to main content
Premium Trial:

Request an Annual Quote

Roka Bioscience Plans 1-for-10 Reverse Stock Split

NEW YORK (GenomeWeb) – Food safety test developer Roka Bioscience announced today that it will effect a 1-for-10 reverse split of its common stock in an effort to regain compliance with the Nasdaq's $1 minimum bid price requirement.

The reverse split, which was approved by shareholders at the company's annual meeting earlier this year, will reduce the number of outstanding shares to about 1.8 million from 17.8 million. The move will affect all Roka shares and proportionally reduce the number of common shares underlying its outstanding Series A preferred stock, warrants, and equity awards.

"Each stockholder's percentage ownership interest and proportional voting power remains unchanged and the rights and privileges of the holders of the company's common stock are unaffected," the company noted in a statement.

The reverse split will take effect at the opening of trading on Oct. 12.

During late morning trading on the Nasdaq, shares of Roka were down 8 percent to $.68.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.